Pfizer COVID-19 mRNA Vaccine's Real-World Performance

Nationwide study in Israel of mass immunization with the BNT162b2 vaccine yields initial efficacy findings similar to those of the phase 3 clinical trial.

Clinical trial results may not accurately reflect outcomes in the real world, where an intervention is applied to a more-diverse population (often with minor variations in drug or vaccine handling, dosage, and timing). Investigators utilized data from Clalit Health Services, which provides healthcare to 53% of Israel's population, to determine the effectiveness of the two-dose Pfizer BNT162b2 mRNA vaccine in preventing COVID-19. Each of 596,618 vaccine recipients between December 20, 2020, and February 1, 2021, was matched 1:1 with an unvaccinated control (with the study population adjusted if a matched control was subsequently immunized).

At 14 to 20 days after the first dose, estimated vaccine effectiveness was 46% (any documented SARS-CoV…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Pfizer COVID-19 mRNA Vaccine's Real-World Performance

Topics

Reviewing Author